Gilead Sciences Inc. (GILD)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

333 LAKESIDE DR FOSTER CITY, CA 94404

Gilead Sciences is a biopharmaceutical company. Co.'s product portfolio includes Truvada, Atripla, Viread and Emtriva for the treatment of human immunodeficiency virus infection; Hepsera and Viread for the treatment of hepatitis B; AmBisome for the treatment of fungal infections; Letairis for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of angina; Vistide for the treatment of cytomegalovirus retinitis; and Cayston for cystic fibrosis patients with Pseudomonas aeruginosa. Co. owns or have rights to a range of trademarks, copyrights and trade names, such as, among others, GILEAD, GILEAD SCIENCES, TRUVADA, VIREAD, and HEPSERA.

Data based on most recent fiscal year report
Market Cap96.337 Billion Shares Outstanding1.306 Billion Avg Volume14.154 Million
1-Yr BETA vs S&P TR Current Ratio2.74 Quick Ratio2.67
View SEC Filings from GILD instead.
Q2 2019 All Institutions Hedge Funds 1
To trade GILD now:
Filers who had this stock in their top 10: 45 11 (1.14%)
13F Filers holding this stock: 1420 120 (12.4%)
Aggregate 13F shares on 06/30/2019: 1.006 Billion 83.59 Million
Aggregate 13F shares on 03/31/2019: 1.004 Billion 83.936 Million
Percent change: 0.19% -0.41%
Funds creating new positions: 108 15
Funds Adding to an existing position: 542 37
Funds closing out their position: 101 17
Funds reducing their position: 629 54
Heat Map Ranking for 06/30/2019 41
Heat Map Ranking for 03/31/2019 61
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GILD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

5.5 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

26.4 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LOFTON KEVIN E

  • Director
64,859 2019-10-01 8

WASHINGTON ROBIN L

  • Director
0 2019-10-01 2

MCHUTCHISON JOHN G CEO AND PRESIDENT

  • Officer
  • Director
0 2019-09-28 3

WHITLEY RICHARD JAMES

  • Director
0 2019-09-27 8

HAMILL LAURA

  • Director
0 2019-09-24 2

LANGE LOUIS G

  • Director
326,375 2019-09-23 0

KRAMER KELLY A. EVP AND CFO

  • Officer
324,089 2019-09-18 1

MANWANI HARISH

  • Director
24,804 2019-09-05 2

WOLD OLSEN PER

  • Director
97,854 2019-08-28 3

PLETCHER BRETT A EVP, GEN COUNSEL & CORP SEC

  • Officer
27,198 2019-08-19 6

MEYERS JAMES R

  • Director
0 2019-08-17 0

MERCIER JOHANNA CHIEF COMMERCIAL OFFICER

  • Officer
0 2019-07-24 2

BISCHOFBERGER NORBERT W

  • Director
0 2019-06-26 0

CARTER PAUL RUTHERFORD

  • Director
0 2019-05-23 0

YOUNG KEVIN

  • Director
0 2019-05-08 0

COGAN JOHN FRANCIS

  • Director
0 2019-05-08 8

WILSON GAYLE E

  • Director
0 2019-05-08 3

BARTON JACQUELINE K

  • Director
0 2019-05-08 2

O'DAY DANIEL PATRICK CHAIRMAN & CEO

  • Officer
  • Director
0 2019-03-01 2

ALTON GREGG H CHIEF PATIENT OFFICER

  • Officer
58,046 2019-02-15 2

MARTIN JOHN C

  • Director
2,887,225 2019-02-06 3

MILLIGAN JOHN F PRESIDENT AND CEO

  • Officer
  • Director
1,574,306 2018-11-27 1

MOORE NICHOLAS G

  • Director
0 2018-03-29 0

MADIGAN JOHN W

  • Director
18,548 2017-05-09 0

DAVIGNON ETIENNE

  • Director
838,652 2016-05-06 0

HILLS CARLA A

  • Director
39,285 2016-05-06 0

DENNY JAMES M

  • Director
281,158 2012-11-28 0

METZA KRISTEN SVP, HUMAN RESOURCES

  • Officer
No longer subject to file 2012-11-01 0

MOORE GORDON EARLE

  • Director
1,063,839 2012-08-14 0

BERG PAUL

  • Director
No longer subject to file 2011-05-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

LOFTON KEVIN E - Director

2019-10-01 M 21,527 d 2,711 64,859.00 direct

LOFTON KEVIN E - Director

2019-10-01 M 21,527 a 64,859 64,859.00 direct

LOFTON KEVIN E - Director

2019-09-27 A 240 a 24,239 0.00 direct

WHITLEY RICHARD JAMES - Director

2019-09-27 A 68 a 6,904 0.00 direct

WOLD OLSEN PER - Director

2019-08-28 S 4,908 $63.91 d 97,854 97,854.00 direct

WOLD OLSEN PER - Director

2019-08-28 M 4,908 $23.76 a 102,762 97,854.00 direct

WOLD OLSEN PER - Director

2019-08-28 M 4,908 d 0 97,854.00 direct

PLETCHER BRETT A - Officer EVP, GEN COUNSEL & CORP SEC

2019-08-19 S 608 $64.35 d 27,198 27,198.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments